Intrasense: Invest Securities adjusts its target

(CercleFinance.com) - Invest Securities confirms its neutral recommendation on the stock 'despite the significant potential' and adjusts its target price to E0.
37 (from E0.35).

' After the disastrous publication of 2023 sales due to China, the group has published 2023 results marked by higher cash consumption ' says the analyst's office.

In 2024, the Group still expects to market its new version of Myrian® 2.12, enriched with AI, and its new oncology solution, called Liflow®, with the submission of the CE marking file in H1," adds Invest Securities.

The analyst believes that the 2026 targets look achievable, but that 2024 will be crucial, and many uncertainties remain regarding the potential contribution of new levers.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.